Decoy20

Bacterial immunotherapy

Also known as IPTN-201

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-06), as a strategic decision by the sponsor

Indaptus discontinued further clinical development in Q2 2026 and has no active clinical programs. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity

Competitive landscape

This drug's own stage for Advanced Colorectal Cancer: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Decoy20: this drugDiscontinuedBacterial immunotherapyMultiple Toll-like receptorsnot yet gradedNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.